Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide begins acting on appetite and blood-sugar regulation within hours of the first dose, but meaningful, visible weight loss takes longer. Most people notice reduced hunger within the first week or two; the scale typically starts to shift within four to eight weeks, with the most significant changes appearing as the dose increases over several months. These are prescription-only medicines, and a prescriber assesses your individual suitability before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide starts working almost immediately at a pharmacological level. As a dual GIP and GLP-1 receptor agonist, it slows gastric emptying and signals fullness to the brain, effects that begin with the first dose. Many people report feeling full sooner at meals within the first three to five days. Hunger between meals can feel quieter than usual.
What you probably won't see yet is a dramatic drop on the scales. The starting dose of 2.5mg is designed to let your system settle, nausea and other gastrointestinal effects are most likely to occur here, and the low dose minimises them. Any weight movement in week one or two is real, but it tends to be modest. Keeping a consistent routine helps: one practical tip our prescribers hear regularly is storing the pen in the same place in the fridge door so the weekly injection becomes as automatic as the Monday morning routine it essentially is.
The early signs that tirzepatide is working can be subtle (smaller portions feeling satisfying, less impulse snacking) and those changes matter even before the number on the scales moves.
At the four-week mark, a prescriber typically moves the dose upward: from 2.5mg to 5mg, then in further 4-week steps toward higher strengths as tolerated. This staged increase is where most people begin to see consistent, week-on-week weight reduction.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed participants across 72 weeks and found average body-weight reductions of around 20–21% at the 15mg maintenance dose. Those results did not arrive at week four, they accumulated across the titration journey. By month three or four, most participants were showing meaningful reductions, with the curve steepening as the dose climbed.
During this phase, gastrointestinal side effects often ease compared with the first few weeks. Energy levels and mobility can improve as weight comes down, which itself tends to support further progress. If you want a clearer picture of how quickly tirzepatide typically works at different doses, the trial evidence offers a useful benchmark, while individual results always vary.
Once a person reaches their highest tolerated dose (for many, somewhere between 7.5mg and 15mg) the rate of weight loss generally continues but can slow as the body adapts. This is normal and expected. If you are curious about how long tirzepatide takes to work at each stage of treatment, the answer depends on dose, individual response, and how adaptation unfolds over time. The plateau seen in long-term trials is not a sign that treatment has stopped working; it reflects the biology of sustained energy-deficit adaptation.
NICE's appraisal of tirzepatide (TA1026) notes that continuing treatment is reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose. That threshold gives you a concrete benchmark for an honest conversation with your prescriber about progress.
For a fuller picture of how the overall treatment timeline compares between doses and different GLP-1 medicines, the Mounjaro overview covers the licensed schedule in context. And if questions come up mid-treatment, our support team is available seven days a week.
Two people on identical doses can see noticeably different results at the same point in treatment. Starting BMI plays a role: someone with a higher starting weight often sees larger absolute losses early on, though the percentage trajectories tend to converge over time. Metabolic history, insulin sensitivity, sleep quality, and how closely dietary changes accompany treatment all influence pace. Patients often ask how long tirzepatide takes to work for them personally, and the honest answer is that these individual factors shape the timeline as much as the dose itself does.
Stress and poor sleep are documented drivers of appetite-hormone disruption; tirzepatide works with your physiology, not independently of it. Alcohol intake, ultra-processed food habits and sedentary patterns can all blunt the response, not because the medicine stops working, but because the hormonal signals it enhances are being pulled in different directions.
None of this means results require perfection. Clinical trial participants achieved significant weight loss without following rigid regimens. The medicine does substantial work; lifestyle factors determine how much of that work translates into consistent progress. Questions about your own pace of response are exactly what aftercare is for. Our clinical team reviews each treatment plan individually, and common questions about progress are covered in detail for patients at every stage. For context on what private treatment involves, the Mounjaro pricing page sets out what a single transparent fee covers. When you're ready to find out whether tirzepatide is clinically suitable for you, speak to our prescribers through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.